Open-Label Study of the Safety and Efficacy of Suprachoroidal CLS-TA Alone or in Combination With Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema (the HULK Trial)

Trial Profile

Open-Label Study of the Safety and Efficacy of Suprachoroidal CLS-TA Alone or in Combination With Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema (the HULK Trial)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Triamcinolone (Primary) ; Aflibercept
  • Indications Diabetes mellitus; Diabetic macular oedema
  • Focus Adverse reactions
  • Acronyms HULK
  • Sponsors Clearside Biomedical
  • Most Recent Events

    • 13 Nov 2017 Results presented in a Clearside Biomedical media release.
    • 13 Nov 2017 According to a Clearside Biomedical media release, preliminary results were presented during the Retina Subspecialty Day of the American Academy of Ophthalmology 2017 Annual Meeting.
    • 08 Nov 2017 According to a Clearside Biomedical media release, the company expects to report preliminary results from the trial on November 10th at the Retina Subspecialty Day of the American Academy of Ophthalmology 2017 Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top